Published in Int J Cancer on March 10, 2002
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol (2007) 1.96
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis (2009) 1.18
Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol (2008) 1.11
The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. Oncotarget (2015) 0.98
Bladder cancer epidemiology and genetic susceptibility. J Biomed Res (2013) 0.95
Contemporary management of low-risk bladder cancer. Nat Rev Urol (2011) 0.93
Genetic susceptibility to bladder cancer risk and outcome. Per Med (2011) 0.90
Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. World J Urol (2012) 0.90
Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma. BMC Cancer (2005) 0.86
Genetic variations rs11892031 and rs401681 are associated with bladder cancer risk in a Chinese population. Int J Mol Sci (2014) 0.83
Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. Hum Mol Genet (2014) 0.83
Incident urothelial cancer in the Malmö Diet and Cancer Study: cohort characteristics and further validation of ezrin as a prognostic biomarker. Diagn Pathol (2014) 0.82
Risk factors, therapy and survival outcomes of small cell and large cell neuroendocrine carcinoma of urinary bladder. Rare Tumors (2014) 0.81
Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features. PLoS One (2014) 0.77
The prognostic value of family history among patients with urinary bladder cancer. Int J Cancer (2014) 0.76
Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. Ther Adv Urol (2016) 0.75
A Functional rs353293 Polymorphism in the Promoter of miR-143/145 Is Associated with a Reduced Risk of Bladder Cancer. PLoS One (2016) 0.75
Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. Genes Cancer (2016) 0.75
Cost of illness of urothelial bladder cancer in Italy. Clinicoecon Outcomes Res (2017) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80
Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet (2008) 12.43
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 8.78
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol (2011) 5.59
Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet (2003) 4.20
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol (2009) 3.69
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology (2011) 3.04
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol (2009) 2.99
Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology (2011) 2.92
The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol (2009) 2.92
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol (2004) 2.82
MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol (2008) 2.77
MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol (2008) 2.76
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Primary hypertension and neurovascular compression: a meta-analysis of magnetic resonance imaging studies. J Neurosurg (2011) 2.75
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol (2006) 2.51
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Transition zone prostate cancer: detection and localization with 3-T multiparametric MR imaging. Radiology (2012) 2.47
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int (2007) 2.25
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol (2006) 2.14
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol (2005) 2.13
Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer. Urology (2009) 2.10
A case of abiraterone acetate withdrawal. Eur Urol (2013) 2.06
Smoking knowledge assessment and cessation trends in patients with bladder cancer presenting to a tertiary referral center. Urology (2011) 2.04
Prediction of the need for an MRI after surgical treatment of symptomatic lumbar herniated disc at discharge: evaluation of the necessity for regular visits at the outpatient clinic. World Neurosurg (2010) 2.03
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
Urinary markers in bladder cancer. Eur Urol (2007) 1.95
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol (2011) 1.90
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol (2006) 1.86
Mammography screening and risk of breast cancer death: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2011) 1.85
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol (2006) 1.82
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81
Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood (2011) 1.79
Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn (2003) 1.78
Age at menopause, cause-specific mortality and total life expectancy. Epidemiology (2005) 1.78
Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol (2010) 1.74
No justification for cervical disk prostheses in clinical practice: a meta-analysis of randomized controlled trials. Neurosurgery (2010) 1.73
Alcohol consumption and risk of prostate cancer in middle-aged men. Int J Cancer (2005) 1.69
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
Lymphoepithelioma-like carcinoma of the urinary tract: a clinicopathological study of 30 pure and mixed cases. Mod Pathol (2007) 1.67
Posterior tibial nerve stimulation in the treatment of urge incontinence. Neurourol Urodyn (2003) 1.67
Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol (2012) 1.66
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy. Urol Oncol (2010) 1.63
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology (2004) 1.62
The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health (2010) 1.62
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol (2006) 1.60
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol (2002) 1.58
Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol (2007) 1.56
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol (2006) 1.56
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol (2009) 1.54
Ultrasound detection of rotator cuff tears: observer agreement related to increasing experience. AJR Am J Roentgenol (2010) 1.54
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol (2006) 1.51
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol (2002) 1.50
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology (2008) 1.50
Executive functions are associated with gait and balance in community-living elderly people. J Gerontol A Biol Sci Med Sci (2008) 1.49
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur Urol (2007) 1.49
Thyroid function and prevalence of anti-thyroperoxidase antibodies in a population with borderline sufficient iodine intake: influences of age and sex. Clin Chem (2005) 1.48
The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol (2006) 1.45
Posterior tibial nerve stimulation in the treatment of idiopathic nonobstructive voiding dysfunction. Urology (2003) 1.43
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 1.43
Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU Int (2011) 1.42
Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology (2007) 1.39
Developments in intravesical therapy for non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther (2010) 1.37
Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology (2009) 1.34
UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol (2006) 1.32
Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest Radiol (2004) 1.30
Risk factors for hypospadias. Eur J Pediatr (2006) 1.27
Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol (2008) 1.26
Fear of movement/(re)injury, disability and participation in acute low back pain. Pain (2003) 1.26
IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys (2006) 1.26
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol (2013) 1.25